NASDAQ:FHTX

Foghorn Therapeutics Competitors

$11.50
-0.28 (-2.38 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$11.20
Now: $11.50
$12.05
50-Day Range
$11.78
MA: $13.57
$16.87
52-Week Range
$11.65
Now: $11.50
$28.26
Volume50,582 shs
Average Volume98,705 shs
Market Capitalization$423.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Foghorn Therapeutics (NASDAQ:FHTX) Vs. SUPN, MYOV, HRTX, ADCT, HRMY, and GBIO

Should you be buying FHTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Foghorn Therapeutics, including Supernus Pharmaceuticals (SUPN), Myovant Sciences (MYOV), Heron Therapeutics (HRTX), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), and Generation Bio (GBIO).

Supernus Pharmaceuticals (NASDAQ:SUPN) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Supernus Pharmaceuticals and Foghorn Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Supernus Pharmaceuticals00203.00
Foghorn Therapeutics00403.00

Supernus Pharmaceuticals presently has a consensus target price of $37.50, suggesting a potential upside of 18.30%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Supernus Pharmaceuticals.

Insider and Institutional Ownership

96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Supernus Pharmaceuticals and Foghorn Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Supernus Pharmaceuticals27.09%20.02%9.67%
Foghorn TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Supernus Pharmaceuticals and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$392.76 million4.27$113.06 million$2.1015.10
Foghorn TherapeuticsN/AN/AN/AN/AN/A

Supernus Pharmaceuticals has higher revenue and earnings than Foghorn Therapeutics.

Summary

Supernus Pharmaceuticals beats Foghorn Therapeutics on 6 of the 8 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Myovant Sciences and Foghorn Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences03302.50
Foghorn Therapeutics00403.00

Myovant Sciences presently has a consensus target price of $31.1667, suggesting a potential upside of 72.57%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Myovant Sciences.

Insider and Institutional Ownership

33.8% of Myovant Sciences shares are held by institutional investors. 3.9% of Myovant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Myovant Sciences and Foghorn Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-201.20%
Foghorn TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Myovant Sciences and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-5.36
Foghorn TherapeuticsN/AN/AN/AN/AN/A

Summary

Foghorn Therapeutics beats Myovant Sciences on 4 of the 6 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Heron Therapeutics and Foghorn Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
Foghorn Therapeutics00403.00

Heron Therapeutics presently has a consensus target price of $26.00, suggesting a potential upside of 45.50%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Heron Therapeutics.

Insider and Institutional Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Foghorn Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
Foghorn TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Heron Therapeutics and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.19$-204,750,000.00($2.50)-7.15
Foghorn TherapeuticsN/AN/AN/AN/AN/A

Foghorn Therapeutics has lower revenue, but higher earnings than Heron Therapeutics.

Summary

Foghorn Therapeutics beats Heron Therapeutics on 5 of the 8 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ADC Therapeutics and Foghorn Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADC Therapeutics01402.80
Foghorn Therapeutics00403.00

ADC Therapeutics presently has a consensus target price of $47.50, suggesting a potential upside of 103.95%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than ADC Therapeutics.

Insider and Institutional Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ADC Therapeutics and Foghorn Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADC TherapeuticsN/AN/AN/A
Foghorn TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares ADC Therapeutics and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$2.34 million685.68$-116,480,000.00($2.36)-9.87
Foghorn TherapeuticsN/AN/AN/AN/AN/A

Foghorn Therapeutics has lower revenue, but higher earnings than ADC Therapeutics.

Harmony Biosciences (NASDAQ:HRMY) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Profitability

This table compares Harmony Biosciences and Foghorn Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harmony BiosciencesN/AN/AN/A
Foghorn TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Harmony Biosciences and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony BiosciencesN/AN/AN/AN/AN/A
Foghorn TherapeuticsN/AN/AN/AN/AN/A

Insider and Institutional Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Harmony Biosciences and Foghorn Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harmony Biosciences00303.00
Foghorn Therapeutics00403.00

Harmony Biosciences presently has a consensus target price of $51.6667, suggesting a potential upside of 83.54%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Harmony Biosciences.

Summary

Foghorn Therapeutics beats Harmony Biosciences on 2 of the 3 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Generation Bio and Foghorn Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
Foghorn TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Generation Bio and Foghorn Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
Foghorn TherapeuticsN/AN/AN/AN/AN/A

Insider and Institutional Ownership

63.3% of Generation Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Generation Bio and Foghorn Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Foghorn Therapeutics00403.00

Generation Bio presently has a consensus target price of $40.60, suggesting a potential upside of 43.46%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Generation Bio.

Summary

Generation Bio beats Foghorn Therapeutics on 2 of the 3 factors compared between the two stocks.


Foghorn Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06-1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87-0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
Gap Down
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Gap Down
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.